- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05535231
A Study to Evaluate the Effect of Turmeric in Healthy Participants
February 23, 2023 updated by: Gaia Herbs Inc.
A Randomized, Double-Blinded, Comparator-Controlled, Crossover Study to Evaluate the Pharmacokinetics of Gaia Full-Spectrum Turmeric Phytocapsules
Turmeric is recognized as a bioactive compound with potential benefits for human health.
This study compares the pharmacokinetic profile of the Turmeric test product to a comparator.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This randomized, double-blinded, comparator-controlled, crossover study will compare the pharmacokinetic profile of the Turmeric test product to a comparator.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jevaneeh Rubio
- Phone Number: 519-341-3364
- Email: jrubio@nutrasource.ca
Study Contact Backup
- Name: Stephanie Recker, M.Sc.
- Phone Number: 519-341-0683
- Email: srecker@nutrasource.ca
Study Locations
-
-
Ontario
-
Guelph, Ontario, Canada, N1G 0B4
- Nutrasource Clinical Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult participants who are 18 to 49 years of age (inclusive).
- In good general health (no active or uncontrolled diseases or conditions) and is able to consume the study product.
- Have a body mass index between 18.5 to 24.9 kg/m2 (inclusive).
- Have normal or acceptable to the investigator heart rate at screening.
Individuals with childbearing potential should have a negative pregnancy test at baseline and must agree to practice an acceptable form of non-hormonal birth control throughout the study, including but not limited to:
- double-barrier method
- non-hormonal intrauterine devices
- complete abstinence from sexual intercourse that can result in pregnancy
- vasectomy of partner at least 6 months prior to the first dose of study product Individuals with the potential to impregnate others must agree to use condoms or other acceptable methods to prevent pregnancy throughout the study. Complete abstinence from sexual intercourse that can result in pregnancy is also acceptable.
- Must have suitable veins for repeated venipuncture.
- Able to swallow pills or capsules whole and without chewing.
Willing and able to comply with the protocol, including:
- Agrees to consume the standardized meals provided at the site during Visit 2 and Visit 3
- Agrees to fast overnight, i.e., no food or liquids for a minimum of 10 hours prior to dosing (except for water, permitted up to 1-hour prior to dosing) on Visit 2 and Visit 3
- Agrees to refrain from consuming grapefruit, pomelo, Seville orange, and starfruit containing foods/beverages 7 days prior to Visit 2 and throughout the study
- Agrees to refrain from caffeine/xanthine and alcohol or alcohol-containing products 48 hours prior to dosing on Visit 2 and Visit 3
- Agrees to refrain from the use/application of treatments/procedures listed in the protocol
- Agrees to maintain the same diet and exercise habits throughout the study
- Agrees not to donate blood or plasma for 30 days after completing the study
- Able to give voluntary consent
Exclusion Criteria:
- Participants who are lactating, pregnant or planning to become pregnant during the study.
- Have a known sensitivity, intolerability, or allergy to any of the standardized study meals/snacks, study products or their excipients.
- Received a vaccine for COVID-19 in the 2 weeks prior to screening or during the study period, current COVID-19 infections, or currently have the post COVID-19 condition as defined by World Health Organization (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis). Note: screened participants who have received a COVID-19 vaccine 2 weeks prior to screening would be eligible to participate after completing a 14-day washout period.
- Have uncontrolled or controlled high blood pressure (≥140 systolic or ≥90 diastolic mmHg) at screening.
- Have a history of heart disease/cardiovascular disease, renal or hepatic impairment/disease, diabetes (Type I or Type II), previously diagnosed or current diagnosis of any psychiatric disorders, unstable thyroid disease, immune disorders and/or immunocompromised (e.g. HIV/AIDS), cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study.
- Major surgery with general anesthesia in the 3 months prior to screening or planned major surgery during the course of the study.
- Have a history of blood clotting disorders.
- Reports a significant blood loss or blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to the first pharmacokinetic visit or a blood donation of more than 450 mL within 56 days prior to the first pharmacokinetic visit.
- Reports donating plasma (e.g., plasmapheresis) within 15 days prior to the first pharmacokinetic visit.
- Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).
- Have gallstones, bile duct obstruction, stomach ulcers, excess stomach acid, or gastroesophageal reflux disease.
- History of alcohol or substance abuse in the 12 months prior to screening or use that to the opinion of the Qualified Investigator may be of a concern for the study.
- Receipt or use of test product(s) in another research study within 28 days prior to baseline or longer if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.
- Any other active or unstable medical conditions or use of medications/supplements/ therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Turmeric test product
Turmeric
|
2 capsules of 490 mg Turmeric are taken with water once
Other Names:
|
Active Comparator: Turmeric comparator
Turmeric
|
2 capsules of 200 mg Turmeric are taken with water once
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics- Area under the plasma concentration-time curve for 8 hours (AUC0-8h)
Time Frame: 8 hours
|
Test products area under the plasma concentration-time curve for 8 hours (AUC0-8h)
|
8 hours
|
Pharmacokinetics- Peak plasma concentration (Cmax)
Time Frame: 8 hours
|
Test products Peak plasma concentration (Cmax)
|
8 hours
|
Pharmacokinetics- Time to reach Cmax (Tmax)
Time Frame: 8 hours
|
Test products Time to reach Cmax (Tmax)
|
8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics- Total area under the curve (observed from 0-8 hours, and extrapolated from 8 hours to infinity) [AUC(0-∞)]
Time Frame: 8 hours
|
Test products Total area under the curve (observed from 0-8 hours, and extrapolated from 8 hours to infinity) [AUC(0-∞)]
|
8 hours
|
Pharmacokinetics- Half-life (T1/2)
Time Frame: 8 hours
|
Test products Half-life (T1/2)
|
8 hours
|
Pharmacokinetics- Terminal elimination rate constant (Kel)
Time Frame: 8 hours
|
Test products Terminal elimination rate constant (Kel)
|
8 hours
|
Safety- participants experiencing adverse events
Time Frame: 8 days
|
The number of participants experiencing Treatment Emergent Adverse Events (TEAEs)
|
8 days
|
Safety- adverse events
Time Frame: 8 days
|
The total number Treatment Emergent Adverse Events (TEAEs)
|
8 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 24, 2022
Primary Completion (Actual)
October 3, 2022
Study Completion (Actual)
October 3, 2022
Study Registration Dates
First Submitted
September 6, 2022
First Submitted That Met QC Criteria
September 8, 2022
First Posted (Actual)
September 10, 2022
Study Record Updates
Last Update Posted (Actual)
February 24, 2023
Last Update Submitted That Met QC Criteria
February 23, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Protective Agents
- Antioxidants
- Turmeric extract
- Curcumin
Other Study ID Numbers
- G02-21-01-T0030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Turmeric test product
-
Boehringer IngelheimCompleted
-
Danone ResearchCompleted
-
GlaxoSmithKlineCompletedDenture RetentionUnited States
-
Coloplast A/SCompletedStoma Site LeakageDenmark
-
Coloplast A/SCompletedCompliance, PatientDenmark
-
Medicis Global Service CorporationCompletedSeborrheic DermatitisUnited States
-
Liquid I.V.University of MemphisNot yet recruiting
-
Nutricia ResearchActive, not recruitingGrowth | Tolerance | Safety | Subjects in Need of a Human Milk Fortifier (HMF)Netherlands, France, Germany, United Kingdom
-
Amplicon ABRecruiting